Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025International Archives of Allergy and Immunology

Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ZKZeynep Yeğin KatranİBİsmet BulutASAndaç Salman

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies low total IgE as a significant predictor of treatment response in chronic spontaneous urticaria patients receiving omalizumab.

Key Points

  • Total IgE levels ≤12.5 IU/mL predicted non-response to omalizumab treatment in chronic spontaneous urticaria patients, highlighting its significance.
  • The study found that omalizumab was effective in 98.2% of included patients, demonstrating consistent improvements in Urticaria Activity Score over time.
  • Multivariate logistic regression analysis confirmed that lower total IgE levels independently indicated non-response in this therapeutic context.
  • These findings underscore the potential for individualized treatment strategies based on total IgE levels among chronic spontaneous urticaria patients.

Cite This Study

Katran et al. (2025) studied this question.

synapsesocial.com/papers/68bb3ef02b87ece8dc9575a5https://doi.org/10.1159/000548107
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study2026
  2. 2Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience2024 · 14 citations
  3. 3Predictors of response to omalizumab for chronic spontaneous urticaria: a retrospective audit on a rural and regional patient cohort in Darwin, Australia2025
  4. 4Efficacy of Standard‐Dose Omalizumab Against Chronic Urticaria: A Real‐World Study2025
  5. 5Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome2024 · 3 citations